AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Chronic kidney disease (CKD) is being diagnosed increasingly worldwide. It is often
identified in individuals with comorbidities, which may increase the already heightened risk …

Aims To determine whether the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation
(GARFIELD-AF) integrated risk tool predicts mortality, non-haemorrhagic stroke/systemic …

Aims Multiple risk scores to predict ischaemic stroke (IS) in patients with atrial fibrillation (AF)
have been developed. This study aims to systematically review these scores, their …

Atrial fibrillation (AF) is the most commonly encountered arrhythmia in clinical practice with
an epidemiological coupling appreciated with advancing age, cardiometabolic risk factors …

Background The net benefit of oral anticoagulation (OAC) with vitamin K antagonists or
direct oral anticoagulants in patients with advanced chronic kidney disease and atrial …

Introduction Balancing antithrombotic therapy for atrial fibrillation (AF) patients undergoing
percutaneous coronary intervention (PCI) remains a clinical challenge due to coexisting …

Abstract Aims CHA2DS2-VASc score is widely utilized for risk stratification and guiding
anticoagulation in patients with atrial fibrillation (AF). Cardiac computed tomography (CCT) …

Background Evaluation of thromboembolic risk is essential in anticoagulated atrial fibrillation
(AF) patients. The CHA 2 DS 2-VASc score is largely validated and recommended by most …